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Genetic improvement in agriculturally important plants has 
contributed to increased food, fiber, and energy production for 
centuries and increasingly during the past 40 years. Until the 
1990s, genetic changes were introduced by relatively uncon-
trolled methods including out-crossing with wild relatives, radia-
tion or chemical mutagenesis followed by back crossing and se-
lection (1, 2). Since 1985, genetically modified (GM) plants have 
been developed using Agrobacterium tumefaciens transforma-
tion vectors (3, 4) or DNA-coupled particle bombardment (5) to 
introduce genes from unrelated sources (e.g. bacteria into soy-
beans). The GM trait is then introduced into diverse genetic va-
rieties by classical breeding for use in various geographical re-
gions and climatic conditions. These methods will help to meet 
growing food demand as the population climbs toward 9 billion 
by 2050 (6–8). Today <200 GM events have been introduced in 
25 crops (primarily soybean, maize, and cotton) and approved 
for production in at least one country (9). 
Approval of GM crops for commercial production and for im-
portation as food or feed follows extensive testing and is the 
responsibility of individual countries or cooperating countries 
(e.g. the European Union). Ideally, regulations follow interna-
tionally vetted guidelines of the Codex Alimentarius Commis-
sion for the assessment of food safety of GM organisms (10), to 
facilitate international trade (11). The allergenicity assessment 
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Abstract 
Premarket, genetically modified (GM) plants are assessed for potential risks of food allergy. The major risk would be trans-
fer of a gene encoding an allergen or protein nearly identical to an allergen into a different food source, which can be 
assessed by specific serum testing. The potential that a newly expressed protein might become an allergen is evaluated 
based on resistance to digestion in pepsin and abundance in food fractions. If the modified plant is a common allergenic 
source (e.g. soybean), regulatory guidelines suggest testing for increases in the expression of endogenous allergens. Some 
regulators request evaluating endogenous allergens for rarely allergenic plants (e.g. maize and rice). Since allergic indi-
viduals must avoid foods containing their allergen (e.g. peanut, soybean, maize, or rice), the relevance of the tests is un-
clear. Furthermore, no acceptance criteria are established and little is known about the natural variation in allergen con-
centrations in these crops. Our results demonstrate a 15-fold difference in the major maize allergen, lipid transfer protein 
between nine varieties, and complex variation in IgE binding to various soybean varieties. We question the value of eval-
uating endogenous allergens in GM plants unless the intent of the modification was production of a hypoallergenic crop.  
Keywords: endogenous allergen, genetically modified, IgE, maize, rice, soybean 
Abbreviations: ANOVA, analysis of variance; GM, genetically modified; HRP, horse radish peroxidase; kU/L, kilounits 
of IgE per liter; mLTP, maize lipid transfer protein; MAb, monoclonal antibody; NFDM, nonfat dry milk; PBST PBS, con-
taining 0.05% Tween 20; PVDF, polyvinylidene difluoride; TCA, trichloroacetic acid; TMB, 3,3´,5,5´-tetramethylbenzidine.  
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is an important focus because food crops in common use are 
generally recognized as safe except for individuals with specific 
food allergies. The primary concern is the potential transfer of a 
major allergen from a different species into a food crop as was 
the case when a Brazil nut 2S albumin was transferred into soy-
bean to improve nutritional quality (12). The Codex (10) calls 
for serum IgE testing if the source of the gene is allergenic. Po-
tential cross-reactivity is also evaluated based upon amino acid 
(protein) sequence identity comparisons to known allergens. If 
a significant sequence match is identified (e.g. >35% identity 
over 80 or more amino acids) using a well-curated allergen da-
tabase such as the peer-reviewed FARRP database (www.allerge-
nonline.org), similar IgE testing would be required (11). The as-
sessment also evaluates the likelihood that the novel protein 
might sensitize susceptible individuals. Factors considered by 
Codex (10) and the European Food Safety Authority (EFSA) (13) 
include stability of the protein in pepsin and abundance in food 
materials. However, the risks of de novo sensitization and sub-
sequent food allergy are difficult to predict and health risks of 
most allergens are relatively low (14). 
The possibility of significant increases in the expression of 
endogenous allergens due to insertion of the transgene is in 
Codex (10) as part of a “compositional analysis of key compo-
nents” including nutrients and anti-nutrients or toxicants and is 
addressed by EFSA (13, 15). Most countries have required eval-
uating endogenous allergens only for GM host plants (gene re-
cipients) that are common causes of allergy (e.g. soybean), but 
not maize. The Codex guideline did not specify testing methods 
or criteria for acceptance or rejection, and the EFSA guidance 
has changed markedly from 2006 to 2011. Testing methods 
accepted by specific regulatory agencies have varied between 
submissions of applications even under the same guidelines 
from 1994 until 2012. Tests of herbicide-tolerant soybean event 
40-3-2 (Monsanto Co., St. Louis, MO, USA) showed no differ-
ences in IgE binding to extracts of the parental line and two 
other commercial soybean varieties using 1D gel immunob-
lotting with a pool of five soybean food challenge–positive al-
lergic subjects (16). The 40-3-2 trait has been bred into ge-
netically diverse commercial varieties and is the dominant GM 
crop globally. Similar studies were not required for insect-re-
sistant maize (MON810), herbicide-tolerant maize, or GM cot-
ton as those crops present little risk of food allergy. Recently, 
the use of complex testing methods (e.g. proteomics) has been 
suggested by some regulatory agencies along with requests 
for testing of crops that rarely cause food allergy (e.g. corn). 
Scientists in the Japanese regulatory agency have performed 
tests to evaluate possible changes in endogenous allergens ex-
pressed in a GM rice event (17). Yet food allergy to rice is ex-
tremely rare and rice is used as a “safe” weaning food in many 
countries (18). While the theoretical possibility of increased ex-
pression of endogenous allergens is a scientifically interesting 
question (19), individuals allergic to a specific food (e.g. soy-
bean or maize) must avoid consuming conventional and GM 
varieties of the crop to remain symptom free. Furthermore, the 
amount and variety of individual commodity crop materials in 
processed foods is highly variable and the commodity is often 
processed in ways that markedly alter allergen content or form 
(e.g. soybean protein isolate, lecithin or fermentation), which 
may alter allergen content and exposure. Yet, risks of food al-
lergy are rarely considered for food products containing non-
GM commodity materials. This study presents results of tests 
evaluating the endogenous allergen content in a small num-
ber of commercially available maize and soybean varieties as 
well as a specific GM soybean event to provide some exam-
ples of variation in the expression of allergens. Based on our 
previous experiences performing studies to evaluate endoge-
nous allergen content of four GM soybean events, appropriate 
tests are difficult to perform and expensive. Submitted dos-
siers often stimulate additional technical questions from regu-
lators that have caused delays of approvals in some countries, 
potentially causing additional indirect costs for food and ani-
mal feed without improving safety. 
Materials and methods 
Maize major allergen, lipid transfer protein 
Pastorello et al. (20) characterized maize LTP (mLTP) as a food 
allergen for Italian subjects that also experience allergic re-
actions to peaches due to a nearly identical LTP. Previously, a 
peptide (AARTTADRRA) corresponding to amino acids 67–76 
of mLTP was synthesized and used to immunize rabbits to pro-
duce antiserum used in this study (RE Goodman unpublished 
at Monsanto, 2002). Natural mLTP was purified from maize fol-
lowing Pastorello’s procedure (20) for use as a standard for im-
munoassays. The identity of the purified mLTP was confirmed 
by LC-MSMS analysis, with 84% coverage of the sequence of 
Tchang et al. (21). Extracts of corn and purified mLTP were sep-
arated in SDS-PAGE, immunoblotted, and detected using the 
rabbit anti-mLTP-peptide serum followed by goat anti-rabbit 
IgG conjugated with horseradish peroxidase (HRP) and Super-
Signal West-DURA chemiluminescent substrate (Thermo Scien-
tific, Rochester, IL, USA). Emitted light from blots was captured 
by a Kodak Gel Logic 440 image station (Carestream Health, 
Rochester, NY, USA). A semiquantitative dot-blot immunoas-
say was developed and validated using equal volume spots of 
a dilution series of reduced and denatured mLTP on nitrocellu-
lose. Samples of nine distinct non-GM maize hybrids (DKC-50-
20, DKC60-19, DKC61-73, DKC63-46, Mo17xB73, N60-B6, N69-
P9, N70- F1, and N76-D3) grown without irrigation in replicate 
plots (n = 2) at the University of Nebraska research station at 
Mead, NE, were extracted. Equal volumes (2 μl) of reduced and 
denatured sodium acetate extracts of grain samples (10 μg to-
tal protein) containing 2% of β-mercaptoethanol (Sigma, St. 
Louis, MO, USA) were heated to 95°C prior to spotting (in trip-
licate) on nitrocellulose. The mLTP was detected and the con-
centration of mLTP estimated from image densities using 1D 
software (Kodak, Carestream Health, Rochester, NY, USA) com-
pared with diluted, purified mLTP. Previous tests (unpublished) 
demonstrated that spotting of equal concentrations of pure 
mLTP and pure LTP spiked into extracts of unrelated plant pro-
tein produced equivalent spots. 
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Soybean endogenous allergen evaluation 
BASF Plant Science (Research Triangle Park, NC, USA), collabo-
rated with EMBRAPA (Empresa Brasileira de Pesquisa Agropec-
uaria, Brazilia, Brazil) to develop a GM soybean, BPS-CV127-9 
that is tolerant to imidazolinone herbicides due to expression 
of a transgene encoding imidazolinone-tolerant acetohydroxy-
acid synthase large subunit (ahasl) from Arabidopsis thaliana. 
The expressed protein was previously characterized as present-
ing a low potential risk of allergenicity based on Codex guide-
lines (10) based on nonallergenic source, lack of sequence simi-
larity to allergens, low abundance, and rapid digestion in pepsin 
using an assay similar to Ofori-Anti et al. (22). Here, we report a 
summary of the study to evaluate potential changes in the ex-
pression of endogenous allergens following Codex (2003) and 
EFSA (2011) guidelines. 
BASF provided full-fat flour samples of the GM event BPS-
CV127 (no. 3410-T), near-isoline (no.3410-I), parental variety 
Conquista (EMBRAPA), two nontransgenic commercial soybean 
lines: MON8001 (no. 3415-M) and Coodetec 217 (no. 3416-C). 
Soybean flour samples and samples of ground and defatted pea-
nuts (Arachis hypogaea), ground navy beans (Phaseolus vulgaris) 
and maize grain were extracted at room temperature in PBS 
with protease inhibitor cocktail (Thermo Scientific). Samples were 
clarified by centrifugation and filtration. Protein concentrations 
were measured by Lowry DC protein assay (BioRad, Hercules, CA, 
USA). Additional extracts of soybeans were prepared for 2D gel 
electrophoresis using a trichloroacetic acid (TCA)/acetone precip-
itation method modified from Natarajan et al. (23). Briefly, sam-
ples of full-fat soybean flour were mixed with a 10% TCA solu-
tion (Sigma) containing 2% of 2-mercaptoethanol (BioRad), in 
cold acetone (Thermo Scientific) and then precipitated at –20°C 
overnight before centrifugation at 10,000 × g for 30 min at 4°C. 
Pellets were washed twice with cold (–20°C) acetone, air-dried, 
and dissolved in a solution of 8 M urea (Invitrogen, Life Technol-
ogies, Grand Island, NY, USA) with 2% CHAPS (Invitrogen). Sam-
ples were clarified by centrifugation, and protein concentrations 
were determined by Bradford assay (BioRad). 
Historical serum or plasma samples from nine soybean al-
lergic and six non-soybean allergic controls (Table 1) that were 
collected under consent and ethical approval at a clinic, or from 
US Food and Drug Administration (FDA) licensed facilities (Sera-
Care Life Sciences, Millford, MA, USA; PlasmaLab International, 
Everett, WA, USA) were tested for IgE binding. Soybean-specific 
IgE levels in soybean allergic donors ranged from 0.8 to 47 kU/l 
as measured by ImmunoCAP® (Phadia AB, Uppsala, Sweden) or 
IMMULITE® (Siemens Healthcare Diagnostics, Inc., Tarrytown, 
NY, USA). The soybean allergic subjects also bound IgE to pea-
nuts ranging from 5 to 100 kU/l. Three of the six control sub-
jects reported allergies to either lupine or pea, but not soybean. 
One-dimensional IgE immunoblotting was performed under 
denaturing conditions (in Laemmli buffer), both with and without 
reducing agent using individual serum and plasma samples as 
described previously (24–26). Samples with β-mercaptoethanol 
were heated to 95°C prior to electrophoresis. Those without re-
ducing agent were not heated. Proteins were separated by elec-
trophoresis in Novex 10–20% tris-glycine minigels (Invitrogen). 
Representative gels were fixed and stained with Colloidal Bril-
Table 1. Human serum and plasma samples 
  Total IgE    Soy-specific IgE (ImmunoCAP* or 
Serum No.  Reported food allergies  kU/L    IMMULITE#) kU/l 
Soybean allergic subjects 
297  Soybean and peanut: anaphylaxis  nd  Soy: 0.8#; peanut: 70# 
714  Soybean: symptoms not specified  nd  Soy: 15.9#; peanut: 22# 
715  Soybean: oral, dermal, respiratory; peanut: anaphylaxis  644  Soybean: 17.8*; peanut: 100* 
716  Soybean: symptoms not specified; peanut, no information  nd  Soybean: 7.2#; peanut: 18# 
719  Soybean and wheat: asthma  1406  Soybean: 22*; peanut: 23* 
721  Soybean: no information; peanut: reported but symptoms not specified  14725  Soybean: 47*; peanut 44* 
RG-LEG-103  Soybean: no information; peanut: hives, throat swelling  1032  Soybean: 12.2*, 1.7#; peanut: 100# 
RG-LEG-105  Soybean: oral itch, facial edema, breathing difficulty  1023  Soybean: 2.3*; peanut: 5* 
RG-LEG-118  Soybean and peanut: hives and edema of face, throat and tongue  915  Soybean: 6.6*; peanut: 100* 
19392-CS  Soybean: angioedema, vomit, EOS G; milk, egg, meat, fruit,  nd  Soy: 68#; peanut: 15# 
     peaches, pears
Non-soybean allergic controls 
RG-71  Allergic to lupin, no symptoms to soybean or peanut  nd  Soybean: 1.5*; peanut: 1.5* 
RG-73  Allergic to pea (no claim of allergy, but weak skin test positive to peanut  nd  Soybean: 0.7*; peanut: 15*  
     and soy) 
RG-74  Allergic to lupin, oral symptoms to peanut, no symptoms to soybean  nd  Soybean: nd; peanut <0.35* 
SNP  No known allergies  nd  nd 
RS-ID-1  Asthma, uncertain cause  nd  Soybean: nd; German cockroach 31* 
RS-ID-3  Asthma, uncertain cause  nd  Soybean: nd; German cockroach 42* 
Nd, not done. 
* ImmunoCAP assay (Phadia, Uppsala, Sweden)
# IMMULITE assay (Siemens Healthcare, Erlangen, Germany)
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liant blue G250 (Sigma). Proteins from gels for immunoblotting 
were electro-transferred to PVDF membranes without fixation 
and then blocked with 5% NFDM in PBST. Soybean allergic or 
control human serum or plasma samples were diluted 1 : 10 or 
1 : 20 (v:v) in 2.5% NFDM in PBST 1 h before addition to mem-
branes and then incubated overnight at 22°C. Membranes were 
washed four times with PBST followed by addition of 1 : 1000 di-
luted monoclonal (MAb) anti-human IgE (SouthernBiotech, Bir-
mingham, AL, USA) conjugated with HRP. Bound antibodies were 
detected with chemiluminescence as described above. A nitro-
cellulose membrane (Invitrogen) spotted with diluted purified 
human MAb IgE (ABCAM Inc., Cambridge, MA, USA) was blocked 
and detected simultaneously with soybean blots to gauge the 
relatively intensity of IgE signals. 
Two-dimensional immunoblotting was performed using in-
dividual human samples to detect IgE binding to four soybean 
samples (GM 3411-T, near-isogenic line 3410-I, parental line 
Conquista, and commercial line 3416-C). Samples represent-
ing 25 μg of TCA-/acetone-precipitated protein were diluted 
to 125 μl in isoelectric focusing (IEF) sample buffer [8 M urea, 
2% CHAPS, 50 mM DTT (Thermo Scientific) containing 0.5% 
ampholyte, pH 3–10 (BioRad)] and applied to 7 cm, pH 3–10 
nonlinear IPG strips (BioRad) in a BioRad PROTEAN IEF system. 
Active rehydration was performed at 50 vdc for 12 h. Separa-
tion was performed using 250 vdc for 15 min; 4000 vdc ramp-
ing for 2 h and 4000 vdc limit-step for 30 000 integrated vhr; 
followed by 500 vdc to maintain focusing. Strips were reduced 
in a solution of 6 M urea, 2% SDS, 0.375 M Tris–HCl, pH 8.8, 
20% glycerol, and 130 mM DTT and then acetylated with 135 
mM iodoacetamide (BioRad). Second dimension (SDS-PAGE) 
separation was performed in NuPAGE® Novex 4–12% Bis-Tris 
ZOOM® Gels (Invitrogen). Representative gels were stained 
with Coomassie blue. Proteins of unstained gels were trans-
ferred to PVDF membranes, blocked with NFDM in PBST, incu-
bated with diluted human samples, and detected as described 
for 1D immunoblots. 
ELISA inhibition was performed using a pool of serum from 
clinically characterized, soybean allergic subjects using a study 
design recommended by European allergen extract regulators 
for testing the potency of allergenic extracts used for diagno-
sis (27). Assays were replicated (n = 3) with fresh extracts of 
each sample. An equal protein pool of all five soybean lines (di-
luted in pH 9.6 carbonate–bicarbonate buffer (Sigma) at 10 μg 
protein per ml) was used to coat Maxisorp ELISA plates (Nunc-
Thermo Scientific). Nonspecific binding was blocked with 1% 
BSA fraction V (Sigma) in PBST. A pool of eight soybean IgE-
positive serum and plasma samples (297, 714, 715, 716, 719, 
721, RE-LEG-103, and RG-LEG- 118) was generated with vol-
umes adjusted (715 and RG-LEG 103 used at half-volumes) to 
provide balanced IgE binding to a variety of soybean proteins 
based on prior direct ELISA and immunoblotting results. A pool 
of six nonsoybean allergic human samples (RG-71, RG-73, RG-
74, SNP, RS-ID1, and RS-ID3) was used as the negative control. 
Triplicate inhibition dilution series were produced for the stan-
dard (pooled soybean) curve and for each individual soybean 
sample by serially diluting the extracts to a final concentration 
of 125, 25, 5, 1, 0.2, or 0.04 μg in 100 μl in a fixed concentration 
of the soybean allergic pool. Individual tubes were mixed and 
held at room temperature for 2 h to allow IgE binding to sol-
uble soybean proteins before adding the mixtures to the soy-
bean-coated ELISA plates. The plates were incubated for 2 h at 
37°C before washing four times with PBST. Monoclonal HRP-
labeled anti-hIgE (SouthernBiotech) was diluted 1:5,000 with 
1% BSA in PBST before addition to the plate, and after 1 h of 
incubation, excess anti-IgE was removed by washing prior to 
the addition of substrate (3,3′,5,5′-tetramethylbenzidine [TMB], 
Sigma). Reactions were stopped after 20 min by the addition of 
100 μl of 1N sulfuric acid (Thermo Scientific). The absorbance at 
450 nm was measured using a Biotek® Powerwave XS2 reader 
(BioTek Instruments, Winooski, VT, USA). The average absor-
bance of uninhibited binding with the soybean nonallergic con-
trol pool was subtracted from test well readings as background 
and represented 100% inhibition of IgE binding (minimum ab-
sorbance). The average absorbance readings from direct serum 
binding to each soybean sample without inhibitor represented 
0% inhibition (maximum absorbance). Inhibition lines were cal-
culated for the standard soybean extract pool and each indi-
vidual soybean extract. The EC50 values (inhibitor concentra-
tion yielding 50% inhibition of binding) were calculated from 
a logistic response model that was fit to inhibition values. The 
EC50 values of individual soybean lines were compared using 
an unbalanced one-way ANOVA (analysis of variance). The GLM 
Procedure of SAS (version 9.1, SAS Institute, Cary, NC, USA) 
was used for the analysis, and a 95% level (P < 0.05) was cho-
sen for significance. 
Results 
Maize LTP 
Validation testing showed the rabbit anti-mLTP-peptide IgG 
is highly specific and the mLTP standard highly pure (data not 
shown). The mLTP dot-blot standard curve (Fig. 1A) was repro-
ducible (replicates not shown) and allowed the determination of 
LTP concentration in grain extracts. Measurement of mLTP from 
the nine non-GM commercial hybrids showed good reproduc-
ibility. The means of the nine hybrids differed by 15-fold across 
hybrids under rain-fed conditions (Fig. 1B). 
Soybean IgE binding 
The total protein concentrations of the five soybean samples ex-
tracted with PBS were similar (15.4–17.8 mg/ml), and the same 
samples extracted following TCA/acetone precipitation were sim-
ilar (8.1–10.2 mg/ml). There were no obvious qualitative differ-
ences of Coomassie stainable protein bands among the five soy-
bean varieties in 1D SDS-PAGE under reducing or nonreducing 
conditions although minor differences in intensity were observed 
for Conquista in high MW bands compared with the other lines 
(Fig. 2). Similarly, the 2D PAGE stained gel patterns of the four 
tested soybean varieties showed only minor qualitative differ-
ences (not shown). 
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One-dimensional immunoblotting patterns of the five soy-
bean lines were similar for soybean allergic sera except for 
subject RG-LEG 118 (lanes 1, 2, and 5 compared with lanes 3 
and 4). However, patterns differed markedly between subjects 
as demonstrated by blots of four representative soybean aller-
gic sera (Fig. 2). Binding to control extracts demonstrate that 
some individuals (e.g. 716) have IgE to other sources of aller-
gens, although IgE binding to navy bean at 34 kDa (lane 7) 
is likely due to binding to cross-reactive carbohydrate deter-
minants (CCD) on phytohemagglutinin and is unlikely to rep-
resent a significant risk of allergy based on our unpublished 
tests with basophils and sera from those with similar binding 
patterns. IgE binding to peanut proteins (lane 9) are prom-
inent for some subjects (RG-LEG 118 and 715), while bind-
ing to maize (lane 11) is generally less intense and less com-
mon. Differences between reducing and nonreducing blots 
are obvious for some subjects, as might be expected due to 
sensitization to multiple subunits of glycinins, which separate 
into acidic and basic subunits under reducing conditions (28). 
There were few notable differences across soybean lines ex-
cept a prominent band that is missing at 60 kDa for soybeans 
MON8001 and CD217 (lanes 3 and 4) for serum RG-LEG 118 
and apparent differences in intensity in high molecular weight 
proteins under nonreducing conditions for plasma 715. Fur-
thermore, 4 of 9 sera showed faint binding to a minor band 
at approximately 12 kDa that was only visible in commercial 
variety CD217 (lane 4) under reduced conditions with serum 
716 (Fig. 2). The results of 1D gel immunoblots showed no 
specific differences in IgE binding to proteins of the trans-
genic soybean line (lane 2) compared with the near-isoline 
(lane 1). The results demonstrated that qualitative and appar-
ent quantitative differences in IgE binding occur between non-
GM commercial soybean lines for some allergic subjects. No 
IgE binding was observed in 1D immunoblots with non-soy-
bean allergic sera (not shown). The 2D immunoblot IgE bind-
ing patterns (Fig. 3A,B) are diverse and difficult to analyze in 
part due to minor migration differences between gels and 
probable technical difficulties in blotting. Replication of blots 
of each sample and serum was not possible due to limited 
availability of serum samples. Thus, no attempt was made to 
quantitatively estimate spot intensities by densitometry. The 
IgE binding spots were visually compared between four soy-
bean lines (transgenic 3411-T, near-isoline 3410-I, commer-
cial line CD217 and parental line Conquista). Spot patterns are 
very similar for individual subjects with exceptions noted be-
low, but differed markedly between subjects as expected from 
1D immunoblotting. Images of immunoblots to all four soy-
bean varieties are shown for two representative subjects (Fig. 
3A), with no obvious differences in binding between the trans-
genic and near-isoline soybean lines. However, two additional 
IgE binding spots (no. 12 and no. 14) are visible in commer-
cial variety 3416-C (CD217) with plasma sample 19392-CS that 
are not visible in the other three soybean lines. Spots no. 18 
and no. 19 are visible in sample 3416-C (CD 217) for plasma 
297 (Fig. 3A), but those spots are not visible in the other ex-
tracts. Immunoblots of the transgenic (3411-T) and near-iso-
line (3410-I) are also shown for four other soybean allergic 
subject’s samples (Fig. 3B), demonstrating remarkably differ-
ent patterns between subjects, but without obvious qualita-
tive differences (and only minor quantitative differences) be-
tween the transgenic and near-isogenic lines. 
Figure 1. (A) Maize LTP SDS-PAGE–stained gel and immunoblotting with 
mLTP-specific rabbit IgG. SDS-PAGE reducing gel, lane (A) 10 μg pro-
tein from maize extract, (B) 0.5 μg purified maize LTP, (C) 10 μg protein 
from maize embryo extract, (M) MW marker. Immunoblot of a PVDF 
membrane blot of an identical gel using rabbit mLTP peptide–specific 
IgG, followed by goat, anti-rabbit-HRP, and chemiluminescent substrate. 
(B) Maize LTP accumulation in nine commercial non-GM varieties of 
maize grown under nonirrigated (dry land) conditions at Mead, Nebraska 
(USA). Grain samples of each maize field plot were extracted triplicate 
and 10 μg of each protein extract was spotted on nitrocellulose mem-
branes, then incubated with rabbit anti-mLTP and then detection an-
tibody and chemiluminscent substrate. Images were captured using a 
Gel Logic 440, and pixel densities were plotted against the mLTP diluted 
standard curve. (B) Mean and standard deviations are plotted showing 
a 15-fold difference in hybrids. 
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IgE inhibition ELISA assay 
Individual soybean allergic (n = 9) and a pool of non-soybean 
allergic (n = 6) serum and plasma samples were tested for IgE 
binding to a pool of all five soybean extracts by direct bind-
ing ELISA to select subjects to pool for the inhibition ELISA (Fig. 
4A). The mean absorbance at 450 nm varied remarkably be-
tween subjects. Soybean allergic sample RG-LEG 105 binding 
hardly differed from the non-allergic control pool, while sam-
ple 715 binding was more than double the next highest binding 
sample (RG-LEG 103) and ten-fold higher than sample 719. This 
ELISA data and 1D immunoblotting patterns were used to se-
lect subjects and concentrations of human samples for the stan-
dard inhibition ELISA pool. For ELISA inhibition, the mean absor-
bance values across replicate assays are plotted in Fig. 4B. The 
fit of the regression lines was high, r2 ≥ 0.99 (data not shown). 
Inhibition values between soybean lines were obviously simi-
lar, although parental Conquista was statistically more potent 
Figure 2. One-dimensional SDS-PAGE of soybean and control samples and IgE Immunoblots. Extracts were separated under reducing and dena-
turing conditions with SDS, mercaptoethanol and heat (Reduced), or under denaturing conditions with SDS, but without mercaptoethanol or heat 
(nonreduced). Representative Coomassie blue stained gels are shown (top). Immunoblots of four representative soybean allergic subject IgE binding 
patterns are shown under reduced and nonreduced conditions with donor samples listed below each set of blots.. Samples were as follows: Lane 1, 
near-isoline 3410-I (10 μg); Lane 2, transgenic line 3411-T (10 μg); Lane 3, commercial variety 3415-M/MON8001 (10 μg); Lane 4, commercial vari-
ety 3416-C/CD217 (10 μg); Lane 5, commercial variety Conquista (10 μg); Lane 6, empty; Lane 7, navy bean (10 μg); Lane 8, empty; Lane 9, peanut (2 
μg); Lane 10, empty; Lane 11, corn (10 μg); Lane 12, molecular weight marker (reduced) or empty (nonreduced); Lane 13, molecular weight marker 
nonreduced). Nitrocellulose strips shown below each image represent dilutions (100 ng to 1 pg) of human IgE spotted and detected along with the 
immunoblots to gauge development intensity.   
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and commercial non-GM, MON8001 was statistically less po-
tent than other soybean lines (Table 2). However, the differences 
of all lines compared to the pooled standard were within a nor-
mal tolerance range (50–200%) for judging the potency of aller-
genic extracts (29, 30). There is less than a two-fold difference in 
the EC50 values across the soybean lines, with observed potency 
being greatest for Conquista (EC50 = 3.11 μg/well) and least for 
MON8001 (3415-M, EC50 = 5.39 μg/well). The EC50 values of the 
transgenic, BPS-CV127-9 (3411-T), and near-isoline (3410-I) were 
similar (4.31 vs 4.68 μg/well, respectively; P = 0.846). 
Figure 3. Representative 2D immunoblots with human serum or plasma samples (listed in figure) of soybean extracts: 3410-I, 3411- T, 3416-C, and 
Conquista. Twenty-five micrograms of protein was separated first in nonlinear pH 3–10 IPG strips and then Bis–Tris 4–12% PAGE in. Spots circled and 
labeled with the same numbers represent the proteins with the same pI and MW between blots. (A) Immunoblots of all four soybean samples with 
two representative human samples demonstrating the additional spots (12, 14, 18, and 19) that were only visible in nontransgenic sample 3416-C. 
(B) Immunoblots of four human samples showing results for only isoline 3410-I and transgenic 3411-T soybeans as the other nontransgenic soy-
bean blots did not differ.  
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Discussion 
The studies reported here are presented as examples that might 
be expected in evaluating potential differences in endogenous 
allergen accumulation in maize and soybean varieties used in 
food production today. The intent was to demonstrate that nat-
ural variation exists between varieties of commodity crops that 
are being transformed for future products as well as show the 
complexity of the analysis. Regulatory agencies in various coun-
tries are asking for similar studies to be performed on every new 
GM event without the benefit of data regarding natural varia-
tion, and without guidance regarding the variation in available 
commercial crops. 
Maize LTP varied up to 15-fold in concentration in mature 
grain across commercial hybrids grown under typical field 
conditions in Nebraska, a major maize producing state in the 
United States. This suggests a wide variation in the major al-
lergen (LTP) content is likely in commercial food and feed 
as well as in extracts used to diagnose allergy by skin prick 
testing. 
We report representative results from a regulatory study 
performed to evaluate a GM soybean event, BPS-CV127-9 fol-
lowing requests for data from EFSA. Those tests were per-
formed using serum and plasma samples from individuals with 
clinically diagnosed soybean allergy or with suspected allergy 
and clear in vitro IgE binding to soybean proteins. The soy-
bean study included 1D immunoblots with individual serum 
samples testing under reducing and nonreducing conditions, 
individual serum samples in 2D immunoblots, and ELISA inhi-
bition using a well-characterized serum pool. This study went 
beyond the requirements of US FDA and EU agencies for the 
regulation of allergenic extracts that are used as diagnostic al-
lergen products. Variation in qualitative IgE binding to proteins 
was evident between non-GM commercial varieties that were 
greater than differences between the GM and isogenic soy-
beans. There were also statistically significant quantitative dif-
ferences between two of the non-GM commercial lines as mea-
sured by ELISA inhibition. Notably, the differences were within 
the likely tolerance limits (50–200%) for diagnostic extracts (29, 
30). However, current regulatory guidelines do not set limits of 
acceptable variation of allergens in GM crops. The inference 
based on compositional analysis of a GM variety compared 
to a near-isogenic variety is that statistically significant differ-
ences would be given intense review. Based on previous deci-
sions evaluating statistically significant differences in nutrient 
composition of GM crops, if the differences fall within statis-
tical tolerance interval of known commercially available lines, 
the product is likely to be accepted by regulators. Yet, formal 
guidelines for endogenous allergens are lacking. 
We believe it is important to reconsider the relevance of 
the question of food safety of GM crops regarding endoge- 
nous allergen expression. First, even though soybean is con-
Table 2. IgE Inhibition ELISA EC50 values: averages from 3 assays 
   Reciprocal% of pooled 
Sample  EC50 (mg/well)  SD  standard EC50† 
Pooled standard  3.86  0.45  – 
3410-I  4.68  0.7  0.82% 
3411-T  4.31  0.11  0.90% 
3415-M  5.39* 0.27  0.72% 
3416-C  4.76 0.35  0.81% 
Conquista  3.11**  0.19  1.24% 
ANOVA comparison of all five soybean lines compared with the stan-
dard pool and each other. 
* Significantly different from the pooled Standard, Dunnett, P < 0.05. 
** Significantly different than all other soybean lines, Tukey, P < 0.05. 
† Reciprocal% EC50: sample EC50/3.86 (Standard Pool) × 100%. 
Acceptance range for a diagnostic extract would be 50–200% (Lorenz 
et al. 2008).   
Figure 4. Direct and Inhibition ELISA IgE binding to soybean extracts. In-
dividual serum and plasma samples were tested for total soybean bind-
ing using direct binding to a pool of soybean extracts coated on the 
plate (A). The data were used to adjust serum concentrations in the pool 
of sera used for inhibition. Inhibition ELISA (B) plots the percent inhibi-
tion of binding resulting from pre-incubating the soybean allergic se-
rum pool (n = 8) with soluble extracts of a standard pool or individual 
extracts of soybean lines at specific protein concentrations. The concen-
trations of specific soybeans required to achieve fifty percent inhibition 
(EC50) are shown (table insert).     
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sidered a commonly allergenic food, the majority of soy-aller-
gic individuals are infants and young children who outgrow 
their soy allergy rather quickly (31), and relatively few subjects 
have severe reactions to soybeans compared with peanut and 
tree nuts. Second, allergenic foods only pose a risk of allergy 
for those who are allergic. There are no data to demonstrate 
that specific doses of allergens are responsible for sensitiza-
tion, while lower doses are tolerogenic. The allergic individu-
als must avoid consumption of foods containing their aller-
genic source to avoid adverse reactions. Food allergy is highly 
specific to the individual, both in the specific allergenic pro-
teins that bind IgE and in the dose of allergen that elicits a re-
action. Severely allergic subjects may only tolerate a few mil-
ligrams of a whole food before reacting, while others tolerate 
gram quantities. Thus, food allergic subjects are told to avoid 
consumption of the foods that elicit their reactions. There are 
no mechanisms to evaluate and segregate hypoand hyper-al-
lergenic varieties (GM or not) in the food supply. 
If tests are required, it is important to consider alternative 
testing methods, costs, and possible conclusions. Acquisition of 
a sufficient number of well-characterized soy-allergic adult se-
rum donors is difficult. For a food crop with a relatively simple 
allergen profile such as maize, with one major allergen (LTP), 
and very rare occurrence of allergy, analytical methods may be 
the only practical way to evaluate endogenous allergen levels. 
But, natural variation in maize LTP levels is high. Thus, an ex-
tremely large increase in the level of maize LTP should neces-
sary to raise concerns for GM maize. In the case of soybeans, 
IgE binding is very complex with many different proteins bound 
by sera from different allergic subjects. A large number of soy 
proteins have been identified as potential soy allergens on the 
basis of IgE binding in various studies (28, 32) and at least 3 
soy proteins (Gly m 4, 5, and 6) qualify as major soy allergens. 
Other investigators have previously shown wide variation in 
the content of allergens in some fruits and commodity crops 
(11, 33), illustrating similar difficulties may be encountered with 
other foods. Some regulators and investigators suggest using 
analytic proteomics methods to measure changes in endog-
enous allergens (34). However, differences in isoform expres-
sion and expression of previously unknown allergens could be 
missed by a proteomic analysis. 
These results and consideration of risks of allergy posed by 
non-GM food crops should raise questions about the relevance 
of such testing as a general safety requirement for GM plants. 
Previously, such evaluations were focused on GM varieties of 
commonly allergenic foods, principally soybean. But, regula-
tors in some Asian countries are asking for similar evaluations 
for GM rice and some European countries have asked for sim-
ilar evaluations of GM maize. Do these tests protect consum-
ers? Those allergic to soybean should avoid soybean contain-
ing foods. Those allergic to maize or rice should avoid maize or 
rice. If regulators are going to continue to ask for similar stud-
ies of new GM crops, there are many issues to address. What 
tests provide sufficient information to allow confident conclu-
sions of safety or of unacceptable risk? Should similar tests 
be required for all new genetic varieties of new crops regard-
less of the source of the genetic variation? And finally, if only 
low allergen expressing varieties are selected for food produc-
tion, will there be a negative impact on production of food and 
feed across diverse environments? Some allergenic proteins are 
pathogenesis related proteins and presumably act to protect 
the plant when attacked by insects or pathogenic microbes or 
when under environmental stress. We strongly recommend re-
moving this requirement from safety testing of new GM crop 
varieties unless there is a very specific question to answer. For 
example, if a developer claimed to have developed a hypoal-
lergenic food crop, then the claim should be verified and the 
product marketed under a different name. 
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